Brighten breaks down how perimenopause and menopause shift insulin sensitivity, fat distribution, appetite, and recovery and where glucagon-like peptide-1 (GLP-1) receptor agonists (think semaglutide/Ozempic, Wegovy, liraglutide, tirzepatide as a related incretin therapy) can fit safely alongside hormone therapy, lifting, protein, and smart lab work
It works through several simultaneous pathways: Semaglutide Weight Loss Results What Does the Research Show
Recommendation to Health Care Specialists Healthcare providers, particularly endocrinologists, and obesity medicine specialists, must be cautious when considering prescribing compounded semaglutide because of the potential hazards associated with its preparation and ingredient sourcing
With Palatins renewed development for ED, trials in the U.S